Pastor-Pascual Francisco, Orts-Vila Paz, Tañá-Sanz Pedro, Tañá-Sanz Santiago, Ruiz-Mesa Ramón, Tañá-Rivero Pedro
Oftalvist, C/ Ruzafa 19, 46004, Valencia, Spain.
Oftalvist, Alicante, Spain.
Eye Vis (Lond). 2024 Apr 1;11(1):14. doi: 10.1186/s40662-024-00380-7.
To assess clinical outcomes after implanting toric, extended-depth-of-focus intraocular lenses (IOLs) to correct low corneal astigmatism in eyes with cataracts.
47 eyes were implanted with the AcrySof IQ Vivity Toric DFT215 IOL. Main outcome measures were refractive error, monocular uncorrected and corrected distance (UDVA/CDVA), uncorrected and distance-corrected intermediate (UIVA/DCIVA), and uncorrected near and distance-corrected near (UNVA/DCNVA) visual acuities, monocular defocus curve, rotational stability, and IOLSAT and QUVID questionnaires. Patients were assessed at 3 months postsurgery.
All eyes had a postoperative spherical equivalent (SE) within ± 0.50 D and 97.87% (n = 46) had a refractive cylinder ≤ 0.50 D. The mean SE and refractive cylinder were - 0.10 ± 0.17 D and - 0.16 ± 0.24 D, respectively. The CDVA was ≥ 20/25 and ≥ 20/32 in 95.74% (n = 45) and 97.87% (n = 46) of eyes, respectively. The DCIVA was ≥ 20/32 in 85.11% (n = 40) of eyes and the DCNVA was ≥ 20/40 in 74.47% (n = 35). The mean values of CDVA, DCIVA, and DCNVA were - 0.02 ± 0.08, 0.14 ± 0.09, and 0.23 ± 0.12 logMAR, respectively. The defocus curve revealed good visual acuity at far and intermediate distances with a depth-of-focus of about 1.75 D. IOL rotation was 0.74 ± 1.13 degrees and all eyes had a rotation of less than 5 degrees. Patients reported either good or very good postoperative vision without eyeglasses under bright-light-conditions at distance (87.80%, 36/41) and intermediate distance (92.68%, 38/41). Between about 63.83%-72.34% (30-34) of patients reported no starburst, halos, or glare, or if experienced, were not bothersome.
The Vivity toric IOL implanted in eyes with low-astigmatism provides accurate refractive outcomes, good visual acuity at different distances and excellent rotational stability. Trial Registration The study was registered with the German Clinical Trials Register (DRKS00030579).
评估植入散光型、扩展焦深人工晶状体（IOL）以矫正白内障患者低度角膜散光后的临床效果。
47只眼植入了AcrySof IQ Vivity Toric DFT215 IOL。主要观察指标包括屈光不正、单眼未矫正和矫正远视力（UDVA/CDVA）、未矫正和距离矫正中间视力（UIVA/DCIVA）、未矫正近视力和距离矫正近视力（UNVA/DCNVA）、单眼散焦曲线、旋转稳定性以及IOLSAT和QUVID问卷。术后3个月对患者进行评估。
所有眼术后等效球镜度（SE）在±0.50 D以内，97.87%（n = 46）的眼屈光柱镜度≤0.50 D。平均SE和屈光柱镜度分别为-0.10±0.17 D和-0.16±0.24 D。分别有95.74%（n = 45）和97.87%（n = 46）的眼CDVA≥20/25和≥20/32。85.11%（n = 40）的眼DCIVA≥20/32，74.47%（n = 35）的眼DCNVA≥20/40。CDVA、DCIVA和DCNVA的平均值分别为-0.02±0.08、0.14±0.09和0.23±0.12 logMAR。散焦曲线显示在远和中间距离有良好视力，焦深约为1.75 D。IOL旋转为0.74±1.13度，所有眼旋转均小于5度。患者报告在明亮光线下远距离（87.80%，36/41）和中间距离（9
